Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (cGMP) quality control. Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients. Source
No articles found.
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
MDisrupt is a Medical Diligence company for the healthtech industry, helping inves...
MDisrupt is a Medical Diligence company for the...
Selecta Biosciences, Inc. is a clinical-stage biotechnology company focused on unl...
Selecta Biosciences, Inc. is a clinical-stage b...
Heska Corporation (NASDAQ: HSKA â News) manufactures, develops and sells advance...
Heska Corporation (NASDAQ: HSKA â News) manuf...
Our mission is to educate and provide an affordable early detection system for the...
Our mission is to educate and provide an afford...
We are a gene therapy company dedicated to developing and commercializing novel tr...
We are a gene therapy company dedicated to deve...
Tocagen is a clinical-stage, cancer-selective gene therapy company developing firs...
Tocagen is a clinical-stage, cancer-selective g...
Join the National Investor Network and get the latest information with your interests in mind.